Adicet Bio, Inc. Debt Conversion, Converted Instrument, Amount
Adicet Bio, Inc. (ACET) reported Debt Conversion, Converted Instrument, Amount of $114.08 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2022-03-15
- Adicet Bio, Inc. debt conversion, converted instrument, amount for the quarter ending 2020-12-31 was -$30.00M.
- Adicet Bio, Inc. debt conversion, converted instrument, amount for fiscal 2020 was $114.08M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 9 month as first filed | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $114.08M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $144.08M 10-Q · filed 2021-11-10 | $2.92M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |